Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
110 stopped studies mapped to Chronic Myeloid Leukemia, BCR-ABL1 Positive and descendants · 75% state a reason
Over the 110 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06680661 | ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis | Phase 2 | suspended | Nov 8, 2024 | Leland Metheny | insufficient funding | Funding |
| NCT05400122 | Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming… | Phase 1 | suspended | Jun 1, 2022 | David Wald | Drugs unavailable | Other (stated, no rule matched) |
| NCT03874858 | A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia(DANTE) | Phase 2 | terminated | Mar 14, 2019 | Novartis Pharmaceuticals | Sponsor decision: The primary endpoint of the core/TF1 was achieved, and the sample size of… | Safety / toxicity |
| NCT05413915 | Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML | Phase 3 | terminated | Jun 10, 2022 | Sarit Assouline | Insufficient patient accrual | Enrollment / accrual |
| NCT03246906 | Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity… | Phase 2 | terminated | Aug 11, 2017 | Fred Hutchinson Cancer Center | Study was terminated prior to enrolling protocol target accrual goal due to declining accrual and… | Safety / toxicity |
| NCT02629692 | Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML… | Phase 1 / Phase 2 | terminated | Dec 14, 2015 | Sun Pharma Advanced Research Company Limited | Closed for administrative, non-safety-related reasons. | Safety / toxicity |
| NCT04216563 | ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With… | Phase 2 | terminated | Jan 2, 2020 | M.D. Anderson Cancer Center | 75% \< Participants, Administrativley Complete | Other (stated, no rule matched) |
| NCT02381548 | Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory… | Phase 1 | terminated | Mar 6, 2015 | National Cancer Institute (NCI) | Other - Adverse Events | Safety / toxicity |
| NCT00776373 | Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive…(UPCC 25406) | Phase 1 / Phase 2 | terminated | Oct 21, 2008 | Abramson Cancer Center at Penn Medicine | not stated | Not stated |
| NCT03333486 | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell… | Phase 2 | terminated | Nov 7, 2017 | Roswell Park Cancer Institute | Futility analysis determined closure | Efficacy / futility |
| NCT01751425 | Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual… | Phase 1 | terminated | Dec 18, 2012 | M.D. Anderson Cancer Center | Per PI Request. 2) No additional benefit was noted with the addition of Ruxolitinib. | Other (stated, no rule matched) |
| NCT03576547 | Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or… | Phase 1 / Phase 2 | terminated | Jul 3, 2018 | M.D. Anderson Cancer Center | The study was terminated early due to slow accrual and low level of interest both by the sponsor… | Enrollment / accrual |
| NCT03615105 | Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA… | Phase 2 | terminated | Aug 3, 2018 | Memorial Sloan Kettering Cancer Center | Low accrual | Enrollment / accrual |
| NCT03746054 | Evaluation of a Cardiovascular Active Prevention in Chronic Myeloid Leukemia on the…(PALERMO) | Phase 3 | terminated | Nov 19, 2018 | University Hospital, Angers | Inclusions stopped on 25MAR2022 due to lack of inclusion Last follow-up on 16APR2024 | Other (stated, no rule matched) |
| NCT02398825 | Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid… | Phase 2 | terminated | Mar 26, 2015 | Gruppo Italiano Malattie EMatologiche dell'Adulto | low enrollment rate | Enrollment / accrual |
| NCT04083170 | Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic… | Phase 2 | terminated | Sep 10, 2019 | Fred Hutchinson Cancer Center | The federal funding period ended. The study was originally intended to be multi-site but was only… | Enrollment / accrual |
| NCT04526795 | Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory… | Phase 1 | terminated | Aug 26, 2020 | M.D. Anderson Cancer Center | Administratively Complete | Other (stated, no rule matched) |
| NCT04808115 | IIT PH1 KDS-1001 in Patients With CML | Phase 1 | withdrawn | Mar 22, 2021 | Duke University | Study halted prematurely, prior to enrollment of first participant. | Enrollment / accrual |
| NCT03884829 | A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS | Phase 1 | terminated | Mar 21, 2019 | Cyclacel Pharmaceuticals, Inc. | Switch to oral formulation of CYC140 (plogosertib) | Other (stated, no rule matched) |
| NCT00522990 | Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias | Phase 1 / Phase 2 | terminated | Aug 30, 2007 | Astex Pharmaceuticals, Inc. | Recommended Phase II dose determined | Other (stated, no rule matched) |
| NCT04793399 | Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic… | Phase 1 / Phase 2 | terminated | Mar 11, 2021 | Fundacion Espanola para la Curacion de la Leucemia Mieloide Cronica | The study has been prematurely terminated due to the onset of 2 dose limiting toxicities in 2… | Safety / toxicity |
| NCT02734823 | Long Term Effects of Tyrosine Kinase Inhibitor Therapy on Ovarian Reserve and Fertility… | — | withdrawn | Apr 12, 2016 | University of Southern California | Lack of accrual | Enrollment / accrual |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME… | Phase 1 | terminated | Mar 18, 2019 | OHSU Knight Cancer Institute | Low accrual | Enrollment / accrual |
| NCT05201183 | A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI)… | Phase 1 / Phase 2 | withdrawn | Jan 21, 2022 | Naoyuki G. Saito, M.D., Ph.D. | insufficient staff and updates in standard practice have made it difficult to recruit participants | Enrollment / accrual |
| NCT00540995 | Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem… | Phase 1 / Phase 2 | terminated | Oct 8, 2007 | City of Hope Medical Center | Unable to safely escalate to TMLI doses that were hypothesized to be effective and less toxic than… | Enrollment / accrual |
| NCT01044745 | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant… | Phase 2 | terminated | Jan 8, 2010 | University of Nebraska | Study was closed to accrual for safety related to the frequency of BK infections. | Safety / toxicity |
| NCT02543749 | DC Vaccination in CML | Phase 1 / Phase 2 | terminated | Sep 7, 2015 | Charite University, Berlin, Germany | not stated | Not stated |
| NCT00573378 | Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia | Phase 2 | terminated | Dec 14, 2007 | University of Michigan Rogel Cancer Center | not stated | Not stated |
| NCT04595851 | Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer… | N/A | terminated | Oct 22, 2020 | University of Michigan Rogel Cancer Center | accrual difficulties | Enrollment / accrual |
| NCT02448095 | Retrospective Evaluation of CML Patients in the National Compassionate Program | — | terminated | May 19, 2015 | Gruppo Italiano Malattie EMatologiche dell'Adulto | lack of interest | Other (stated, no rule matched) |
| NCT04006847 | Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid… | Phase 1 / Phase 2 | terminated | Jul 5, 2019 | Milton S. Hershey Medical Center | Product complaint | Other (stated, no rule matched) |
| NCT00968864 | T-cell Depleted Alternative Donor Transplantation | Phase 2 | terminated | Aug 31, 2009 | Wake Forest University Health Sciences | Sponsor/ PI leaving institution, no plans to continue this research at this time | Other (stated, no rule matched) |
| NCT03696537 | IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT | Phase 1 | terminated | Oct 4, 2018 | Naoyuki G. Saito, M.D., Ph.D. | Extreme toxicity | Safety / toxicity |
| NCT02228382 | Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive… | Phase 4 | terminated | Aug 29, 2014 | Pfizer | not stated | Not stated |
| NCT03519984 | EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With… | Phase 1 | terminated | May 9, 2018 | University of Southern California | Study drug supply issue | Drug supply |
| NCT02627677 | A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia(OPTIC-2L) | Phase 3 | terminated | Dec 11, 2015 | Ariad Pharmaceuticals | The study was stopped due to operational feasibility and not due to any safety concerns | Safety / toxicity |
| NCT02795520 | Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute… | Phase 1 / Phase 2 | terminated | Jun 10, 2016 | OncoTherapy Science, Inc. | slow patient accrual | Enrollment / accrual |
| NCT02078960 | A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given… | Phase 1 / Phase 2 | terminated | Mar 5, 2014 | Teva Branded Pharmaceutical Products R&D, Inc. | Inability to accrue additional sites and enroll an adequate number of subjects. | Enrollment / accrual |
| NCT00210119 | Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in…(AFR22) | Phase 2 | terminated | Sep 21, 2005 | Institut Bergonié | not stated | Not stated |
| NCT04464889 | HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem… | Phase 1 | withdrawn | Jul 9, 2020 | Medigene AG | Medigene transfered all rights to a new Sponsor | Other (stated, no rule matched) |
| NCT01663766 | Phase I Study of Milatuzumab for Graft Versus Host Disease | Phase 1 | terminated | Aug 13, 2012 | Gilead Sciences | PIs agreed no safety signals were shown, drug did not appear to lessen the risk of preventing GVHD… | Safety / toxicity |
| NCT03602898 | Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate… | Phase 2 | withdrawn | Jul 27, 2018 | Fred Hutchinson Cancer Center | Insufficient funding | Funding |
| NCT01131325 | Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations(MACS1148) | Phase 4 | terminated | May 26, 2010 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT02973711 | A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML | Phase 1 / Phase 2 | withdrawn | Nov 25, 2016 | University of Michigan Rogel Cancer Center | lack of funding | Funding |
| NCT03739606 | Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer | Phase 2 | withdrawn | Nov 14, 2018 | City of Hope Medical Center | RSS recommendation | Other (stated, no rule matched) |
| NCT01300611 | TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation(USBTXA127CBT) | Phase 1 | terminated | Feb 21, 2011 | Tarix Pharmaceuticals | not stated | Not stated |
| NCT02782403 | Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase… | Phase 1 | terminated | May 25, 2016 | M.D. Anderson Cancer Center | Terminated per PI's request at the time of CR. Study was closed due to low/slow accrual due to… | Enrollment / accrual |
| NCT03807063 | Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood… | Phase 1 | withdrawn | Jan 16, 2019 | Fred Hutchinson Cancer Center | Insufficient funding | Funding |
| NCT02906696 | Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After… | Phase 2 | terminated | Sep 20, 2016 | M.D. Anderson Cancer Center | Terminated per PI's request due to competing priorities. | Other (stated, no rule matched) |
| NCT02231853 | Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells… | Phase 1 | terminated | Sep 4, 2014 | National Heart, Lung, and Blood Institute (NHLBI) | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 20 days agoSource updated Sep 10, 2026source: clinicaltrials